Compare Gaming and Leisure Properties Inc. Common Stock (GLPI) vs NeoGenomics Inc. Common Stock (NEO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gaming and Leisure Properties Inc. Common Stock vs NeoGenomics Inc. Common Stock — how do they compare? Gaming and Leisure Properties Inc. Common Stock trades at $38.13 (market cap $11.11B), while NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.17B). The key difference: Gaming and Leisure Properties Inc. Common Stock is far larger — about 5.1× NeoGenomics Inc. Common Stock's market cap, and Gaming and Leisure Properties Inc. Common Stock pays a 8.59% dividend while NeoGenomics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gaming and Leisure Properties Inc. Common Stock for 0 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| GLPI | NEO | |
|---|---|---|
Market Cap | $11.11B | $2.17B |
Volume | 2,244,030 | 1,615,943 |
Sector | Real Estate | Health |
52-Week High | $49.82 | $19.91 |
52-Week Low | $37.59 | $7.19 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $19.17B | $2.47B |
Dividend Yield | 8.59% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gaming and Leisure Properties Inc. Common Stock
Gaming and Leisure Properties Inc. is a real estate investment trust that acquires, finances, and owns casino and gaming properties, which it leases to gaming operators under triple-net lease arrangements. It was the first publicly traded REIT focused on the gaming real estate sector in North America.
Read more on GLPI →About NeoGenomics Inc. Common Stock
NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →
